Celgene (CELG) announced that the European Commission (EC) has approved its Revlimid (lenalidomide) for relapsed/refractory mantle cell lymphoma, a rare subtype of non-Hodgkin's lymphoma that is very resistant to treatment. Fewer than half of sufferers survive longer than five years. The data supporting approval was generated in a Phase 2 study in 254 patients who failed to respond to their last treatment and had relapsed one to three times. Those treated with Revlimid experienced progression-free survival of 8.7 months compared to 5.2 months for investigator's choice of therapy (p=0.004) with a 39% reduction in the risk of death over the study period (hazard ratio = 0.61).